Premium
Notes on streptozotocin in metastatic insulinoma
Author(s) -
Vogel Thomas T.
Publication year - 1971
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930030502
Subject(s) - medicine , insulinoma , streptozotocin , toxicity , insulin , diabetes mellitus , octreotide , bone marrow , surgery , endocrinology , somatostatin
A case of limited success with streptozotocin in overwhelming metastatic insulinoma is reported for illustration of clinical management and possible toxic effects of the drug. An initial dose of 1.5 g/m 2 and an interval of administration no more frequent than 1–2 weeks is favored. Acute renal failure and bone marrow suppression followed the last and largest intravenous dose of 8 g/m 2 . Insulin immunoassay levels and glucose or caloric requirements were reduced, but the patient did not survive. Niacin‐amide and an intra‐arterial route of administration may avoid toxicity in clinical use of this valuable drug.